Longevity Biotech is a brand that specializes in developing a new class of therapeutic candidates called Hybridtides®. They are focused on delivering clinically transformative products that address the most challenging aspects of medicine today. The unique Hybridtide® scaffold provides critical enhancements over previous peptide development efforts.

Hybridtides® are synthetic peptides based on the seminal work by Prof. Samuel Gellman at the University of Wisconsin. These peptides have a unique peptidomimetic scaffold that is both digestively and structurally stable.

This stability is achieved through the incorporation of α and β amino acids. The diverse peptide engineering opportunities derived from this fundamental scaffold allow for the development of innovative products. Building on the Hybridtide® scaffold, Longevity Biotech has created a streamlined, data-driven process to deliver peptides orally.

They use the Hybridtide® Optimization Toolkit (HOT®) to evaluate and optimize the peptides for absorption. The resulting lead candidate is then evaluated in vivo for absolute bioavailability. Longevity Biotech has primarily applied the Hybridtide® scaffold to target receptors in the class B-GPCR family of drug targets.

Their neuroscience and diabetes programs, based on Hybridtides®, are currently in preclinical development, along with several other projects. The brand has a team of worldwide experts in peptide drug development programs. With deep and broad expertise, they bring new biological products into and through clinical trials.

The leadership team and advisors have a wealth of experience in the field. Contact Longevity Biotech to learn more about their innovative approach to therapeutic development